17 research outputs found
Meningococcal vaccination: Recommendations of the advisory committee on immunization practices, United States, 2020
© 2020. This report compiles and summarizes all recommendations from CDC\u27s Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States. As a comprehensive summary and update of previously published recommendations, it replaces all previously published reports and policy notes. This report also contains new recommendations for administration of booster doses of serogroup B meningococcal (MenB) vaccine for persons at increased risk for serogroup B meningococcal disease. These guidelines will be updated as needed on the basis of availability of new data or licensure of new meningococcal vaccines. ACIP recommends routine vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY) for adolescents aged 11 or 12 years, with a booster dose at age 16 years. ACIP also recommends routine vaccination with MenACWY for persons aged ≥2 months at increased risk for meningococcal disease caused by serogroups A, C, W, or Y, including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor (e.g., eculizumab [Soliris] or ravulizumab [Ultomiris]); persons who have anatomic or functional asplenia; persons with human immunodeficiency virus infection; microbiologists routinely exposed to isolates of Neisseria meningitidis; persons identified to be at increased risk because of a meningococcal disease outbreak caused by serogroups A, C, W, or Y; persons who travel to or live in areas in which meningococcal disease is hyperendemic or epidemic; unvaccinated or incompletely vaccinated first-year college students living in residence halls; and military recruits. ACIP recommends MenACWY booster doses for previously vaccinated persons who become or remain at increased risk. In addition, ACIP recommends routine use of MenB vaccine series among persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease, including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor persons who have anatomic or functional asplenia; microbiologists who are routinely exposed to isolates of N. meningitidis; and persons identified to be at increased risk because of a meningococcal disease outbreak caused by serogroup B. ACIP recommends MenB booster doses for previously vaccinated persons who become or remain at increased risk. In addition, ACIP recommends a MenB series for adolescents and young adults aged 16-23 years on the basis of shared clinical decision-making to provide short-term protection against disease caused by most strains of serogroup B N. meningitidis
Serogroup-Specific Meningococcal Carriage by Age Group::A Systematic Review and Meta-Analysis
Objective Neisseria meningitidis carriage prevalence has known variation across the lifespan, but it is unclear whether carriage varies among meningococcal capsular groups. Therefore, we aimed to characterise group-specific meningococcal carriage by age group and world region from 2007 to 2016.Design Systematic review and meta-analysis.Data sources MEDLINE, Embase, Global Health Database, WHO Global Health Library, Web of Science, Current Contents Connects, China National Knowledge Infrastructure and Wanfang were systematically searched. Database searches were conducted through July 2018 and Google Scholar forward searches of included studies were conducted through August 2018. References of included studies and relevant conference abstracts were also searched to identify additional articles for inclusion.Eligibility criteria Studies were eligible for inclusion if they reported capsular group-specific meningococcal carriage in a healthy population of a specified age group and geographical region. For this review, only studies conducted between 2007 and 2016 were included.Data extraction and synthesis Data were independently extracted by two authors into Microsoft Access. Studies were assessed for risk of bias using the Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data. Studies eligible for inclusion in quantitative analyses by pre-specified age groups were pooled using random effects meta-analyses. Results are reported by capsular group, age group and WHO region. Where meta-analyses were not appropriate, study results were discussed narratively.Results 7511 articles were identified and 65 were eligible for inclusion. Adolescents and young adults were the focus of many studies (n=24), especially in the Americas and Europe. Studies from China and Africa, typically, included data from a wider age range. The overall carriage prevalence varied markedly by age group and region. Based on the available data, 21 studies were included in meta-analyses reporting serogroup carriage for: all ages in Africa, 18–24-year olds in the Americas, and 11–17 and 18–24-year olds in Europe. Capsular groups W, X, Y and ‘other’ (non-ABCWXY, including non-groupable) were the most prevalent in Africa, and 5–17-year olds had higher carriage prevalence than other age groups. ‘Other’ serogroups (11.5%, 95% CI 1.6% to 16.1%) were the most common among 18–24-year olds from the Americas. In Europe, 18–24-year old were carriers more frequently than 11–17-year olds, and groups B (5.0%, 95% CI 3.0% to 7.5%), Y (3.9%, 95% CI 1.3% to 7.8%) and ‘other’ (6.4%, 95% CI 3.1% to 10.8%) were the most commonly carried in the older age group.Conclusions Of the age groups included in the analysis, carriage patterns by age were similar across capsular groups within a region but differed between regions. Data gaps remain for age- and capsular group-specific carriage in many regions, especially in the Eastern Mediterranean and South-East Asia. As such, clear and robust conclusions about the variation of capsular group-specific carriage by age group and WHO region were unable to be determined
The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination.
Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia worldwide and is associated with high case fatality rates and serious life-long complications among survivors. Twelve serogroups are recognised, of which six (A, B, C, W, X and Y) are responsible for nearly all cases of invasive meningococcal disease (IMD). The incidence of IMD and responsible serogroups vary widely both geographically and over time. For the first time, effective vaccines against all these serogroups are available or nearing licensure. Over the past two decades, IMD incidence has been declining across most parts of the world through a combination of successful meningococcal immunisation programmes and secular trends. The introduction of meningococcal C conjugate vaccines in the early 2000s was associated with rapid declines in meningococcal C disease, whilst implementation of a meningococcal A conjugate vaccine across the African meningitis belt led to near-elimination of meningococcal A disease. Consequently, other serogroups have become more important causes of IMD. In particular, the emergence of a hypervirulent meningococcal group W clone has led many countries to shift from monovalent meningococcal C to quadrivalent ACWY conjugate vaccines in their national immunisation programmes. Additionally, the recent licensure of two protein-based, broad-spectrum meningococcal B vaccines finally provides protection against the most common group responsible for childhood IMD across Europe and Australia. This review describes global IMD epidemiology across each continent and trends over time, the serogroups responsible for IMD, the impact of meningococcal immunisation programmes and future needs to eliminate this devastating disease
Recommended adult immunization schedule, United States, 2020
In October 2019, the Advisory Committee on Immunization
Practices (ACIP) voted to approve the Recommended
Adult Immunization Schedule for Ages 19
Years or Older, United States, 2020. The 2020 adult immunization
schedule, available at www.cdc.gov/vaccines
/schedules/hcp/imz/adult.html, summarizes ACIP recommendations
in 2 tables and accompanying notes (Figure).
The full ACIP recommendations for each vaccine are available
at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
The 2020 schedule has also been approved by the director
of the Centers for Disease Control and Prevention
(CDC) and by the American College of Physicians (www
.acponline.org), American Academy of Family Physicians
(www.aafp.org), American College of Obstetricians and
Gynecologists (www.acog.org), and American College of
Nurse-Midwives (www.midwife.org)
Production and Quality Assessment of Custard from Cornstarch Fortified with Roasted African Yam Bean and Solar Dried African Bush Mango
Corn, roasted African yam bean and solar dried bush mango, were processed into flours and was used to produce custard. The samples, cornstarch: roasted African yam bean: African bush mango flours (CSTF: AYBF: ABMF) were blended in the ratios of 90:5:5, 85:5:10, 80:5:15, 75:5:20, 70:5:25, respectively and were evaluated for chemical composition, functional properties, microbial quality and sensory properties. The addition of African bush mango significantly (p < 0.05) increased the moisture, crude fat, crude protein, ash content, and crude fiber from 7.27 to 8.87, 1.42 to1.85, 2.14 to 2.78, 7.45 to 7.89 and 1.32 to 1.69%, respectively while the addition of African bush mango decreased the carbohydrate from 80.39 to 76.92%, pro-vitamin A, vitamin B1, B2, B9 and vitamin C increased with addition of African bush mango from 0.88 to 1.82, 0.85 to 1.63, 0.39 to 0.62, 0.21 to 0.35 and 0.84 to 1.64 (%), respectively. The anti-nutrients phytate, oxalate, heamaglutenin, trypsin inhibitor, tannins, hydrogen cyanide and saponin significantly (p < 0.05) decreased from 2.89 to1.43 mÂg100g-1, 0.59 to 0.47mg/100g-1, 0.76 to 0.48 HIUmg-1, 0.69 to 0.54 TIUmg-1, 19.94 to 11.91mg/100g-1, 2.43 to 0.82 mg/100g-1 and 0.59 to 0.42 mg/100g-1, respectively. The addition of African bush mango increased the swelling capacity, wettability, viscosity and gelation capacity from 4.32 to 5.75%, 37.33 to 43.67 sec, 1.31 to 2.278 cp and 21.67 to 23.33% while water absorption capacity and bulk density decreased with an increased African bush mango from 14.67 to10.67% and 1.18 to 0.84 g/dm-3. The total viable count ranged from 2.0x104 cfug-1 to 1.0x104cfu/g, except for the control which has high total viable count of 8.6 x103cfu/g
Recommended from our members
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
Public domain journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]